TY - JOUR
T1 - Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era
AU - Serrano-aroca, Ángel
AU - Takayama, Kazuo
AU - Tuñón-molina, Alberto
AU - Seyran, Murat
AU - Hassan, Sk. Sarif
AU - Pal Choudhury, Pabitra
AU - Uversky, Vladimir N.
AU - Lundstrom, Kenneth
AU - Adadi, Parise
AU - Palù, Giorgio
AU - Aljabali, Alaa A. A.
AU - Chauhan, Gaurav
AU - Kandimalla, Ramesh
AU - Tambuwala, Murtaza M.
AU - Lal, Amos
AU - Abd El-aziz, Tarek Mohamed
AU - Sherchan, Samendra
AU - Barh, Debmalya
AU - Redwan, Elrashdy M.
AU - Bazan, Nicolas G.
AU - Mishra, Yogendra Kumar
AU - Uhal, Bruce D.
AU - Brufsky, Adam
PY - 2021/4/7
Y1 - 2021/4/7
N2 - Therapeutic options for the highly pathogenic human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic coronavirus disease (COVID-19) are urgently needed. COVID-19 is associated with viral pneumonia and acute respiratory distress syndrome causing significant morbidity and mortality. The proposed treatments for COVID-19 have shown little or no effect in the clinic so far. Additionally, bacterial and fungal pathogens contribute to the SARS-CoV-2-mediated pneumonia disease complex. The antibiotic resistance in pneumonia treatment is increasing at an alarming rate. Therefore, carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives constitute a promising alternative due to their wide-spectrum antimicrobial activity, biocompatibility, biodegradability, and capacity to induce tissue regeneration. Furthermore, the antimicrobial mode of action is mainly physical (e.g., membrane distortion), characterized by a low risk of antimicrobial resistance. In this Review, we evaluated the literature on the antiviral activity and broad-spectrum antimicrobial properties of CBNs. CBNs had antiviral activity against 13 enveloped positive-sense single-stranded RNA viruses, including SARS-CoV-2. CBNs with low or no toxicity to humans are promising therapeutics against the COVID-19 pneumonia complex with other viruses, bacteria, and fungi, including those that are multidrug-resistant.
AB - Therapeutic options for the highly pathogenic human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic coronavirus disease (COVID-19) are urgently needed. COVID-19 is associated with viral pneumonia and acute respiratory distress syndrome causing significant morbidity and mortality. The proposed treatments for COVID-19 have shown little or no effect in the clinic so far. Additionally, bacterial and fungal pathogens contribute to the SARS-CoV-2-mediated pneumonia disease complex. The antibiotic resistance in pneumonia treatment is increasing at an alarming rate. Therefore, carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives constitute a promising alternative due to their wide-spectrum antimicrobial activity, biocompatibility, biodegradability, and capacity to induce tissue regeneration. Furthermore, the antimicrobial mode of action is mainly physical (e.g., membrane distortion), characterized by a low risk of antimicrobial resistance. In this Review, we evaluated the literature on the antiviral activity and broad-spectrum antimicrobial properties of CBNs. CBNs had antiviral activity against 13 enveloped positive-sense single-stranded RNA viruses, including SARS-CoV-2. CBNs with low or no toxicity to humans are promising therapeutics against the COVID-19 pneumonia complex with other viruses, bacteria, and fungi, including those that are multidrug-resistant.
KW - General Engineering
KW - General Materials Science
KW - General Physics and Astronomy
KW - COVID-19
KW - carbon-based nanomaterials
KW - carbon dots
KW - tissue regeneration
KW - SARS-CoV-2
KW - antiviral properties
KW - pneumonia
KW - fullerene
KW - graphene
KW - Humans
KW - Carbon
KW - Antiviral Agents/pharmacology
KW - Pneumonia, Viral/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85105090399&partnerID=8YFLogxK
U2 - 10.1021/acsnano.1c00629
DO - 10.1021/acsnano.1c00629
M3 - Article
C2 - 33826850
SN - 1936-0851
VL - 15
SP - 8069
EP - 8086
JO - ACS Nano
JF - ACS Nano
ER -
